Positive Reimbursement Changes in BPH Treatment Drives the U.S. Urological Device Market: Led by American Medical Systems, Olympus and Karl Storz
According to a recent U.S. urology report, increased incidences of benign prostatic hyperplasia (BPH) are expected to be significant in the coming years. Approximately half of men exhibit evidence of BPH by age 50 years, a proportion which increases to 75% by age 80.
November 25, 2014 20:37 ET | Source: iData Research
VANCOUVER, BC, Nov. 25, 2014 (GLOBE NEWSWIRE) -- via PRWEB - According to an in-depth U.S. urology report, from iData Research, the leading global authority in medical device market research, the U.S. urological market is expected to approach $3 billion by 2020. Growth can be attributed to the increasing incidence of BPH and reimbursement changes.
More than 125 CPT and ICD-9 procedure codes as well as over 500 responses from surveys were examined and incorporated into analyses for procedure volumes. The research included studies for such urological disorder treatment devices for BPH, which describes the enlargement of the prostate, stone management nephrostomy, urodynamic, urinary incontinence and erectile dysfunction management.
iData's research concluded approximately over 230,000 BPH procedures are expected to be performed by 2020. "The population of males over 65 years of age is a significant driver for non-drug BPH treatment" says Dr. Kamran Zamanian, CEO of iData. "Drug treatments can lose efficacy over time. Approximately half of men exhibit evidence of BPH by age 50, a proportion of which increases to 75% by age 80."
Click the link above for access to the article
#ICD10 #ICDRemediator #ICD10Matters #HealthIT
Get Remediator to assist in your readiness for the ICD-10 switchover www.icdremediator.com
No comments:
Post a Comment